Osi Pharmaceuticals Inc

Osi Pharmaceuticals — Investor Day (November 2007)

140 slides from Osi Pharmaceuticals's investor day presentation, Nov 29, 2007

  1. Slide 1: Welcome to OSI's Analyst Day

    Slide 1: Welcome to OSI's Analyst Day

    Shaping Medicine, Changing Lives Welcome to OSI's Analyst Day November 29, 2007 Exhibit 99.1

  2. Slide 2: Forward-looking Statements

    Slide 2: Forward-looking Statements

    OSI Pharmaceuticals Forward-looking Statements OSI's presentations today contain forward-looking statements. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might

  3. Slide 3: Strategic Overview

    Slide 3: Strategic Overview

    Shaping Medicine, Changing Lives Colin Goddard, Ph.D. Chief Executive Officer Analyst Day November 29, 2007 CEO Gold Standard Founding Member Strategic Overview

  4. Slide 4: OSI Analyst Day Agenda

    Slide 4: OSI Analyst Day Agenda

    OSI Analyst Day Agenda Time Activity Speaker 12:30 Welcome Kathy Galante 12:35 Strategic Overview Colin Goddard, Ph.D. 12:50 Oncology Gabriel Leung David Epstein, Ph.D. Karsten Witt, M.D. 2:00 Diabetes & Obesity Anker Lundemose, M.D., Ph.D. Jim McCormack, Ph.D., D.Sc Jonathan Rachman, M.D., Ph.D. 2:

  5. Slide 5: OSIP Exiting 2007: Re-Establishing Growth

    Slide 5: OSIP Exiting 2007: Re-Establishing Growth

    OSIP Exiting 2007: Re-Establishing Growth Weathering the Classic "First Product" Transition Years to/from Launch: -1 0 +1 +2 Science Driven Expectation Financial Performance 'Chapter Two' Can Only Really Begin When Financial Performance Catches Up to Science Driven Expectations Eyetech Acquisition -

  6. Slide 6: OSIP Exiting 2007: Re-Establishing Growth

    Slide 6: OSIP Exiting 2007: Re-Establishing Growth

    OSIP Exiting 2007: Re-Establishing Growth Weathering the Classic "First Product" Transition Years to/from Launch: -1 0 +1 +2 Science Driven Expectation Financial Performance 'Chapter Two' Can Only Really Begin When Financial Performance Catches Up to Science Driven Expectations Short Squeeze Around

  7. Slide 7: Delivering Financial Performance

    Slide 7: Delivering Financial Performance

    Delivering Financial Performance Turning the Corner to Profitability in 2007 Tarceva Sales $MM (except per share amounts) 3Q2007 Nine Months 2007 Nine Months 2006 Guidance U.S. Sales $101.00* $304.00 $296.00 ROW Sales $125.00 $331.00 $164.00 Global Sales $226.00 $635.00 $460.00 >$860 OSI P&L Highlig

  8. Slide 8: OSIP: What to Expect in 2008/9

    Slide 8: OSIP: What to Expect in 2008/9

    OSIP: What to Expect in 2008/9 Laying the Foundation for Sustained Growth "Continued Highly Disciplined R&D Investment Allowing Us to Further Leverage Tarceva Revenues and DP-IV Royalty Top-line in 2008 While Delivering Second Half SATURN & BETA Data and Continuing to Nurture a High Quality Early Pi

  9. Slide 9: OSIP: What to Expect in 2008/9

    Slide 9: OSIP: What to Expect in 2008/9

    OSIP: What to Expect in 2008/9 Laying the Foundation for Sustained Growth "Continued Highly Disciplined R&D Investment Allowing Us to Further Leverage Tarceva Revenues and DP-IV Royalty Top-line in 2008 While Delivering Second Half SATURN & BETA Data and Continuing to Nurture a High Quality Early Pi

  10. Slide 10: OSIP: What to Expect in 2008-9

    Slide 10: OSIP: What to Expect in 2008-9

    OSIP: What to Expect in 2008-9 Next 11/2 - 2 Years Can Deliver Substantial Upside Convince the world of the robust continued global growth of Tarceva Tarceva as a "$2bn+" product & not a "peak $1bn product with no growth" SATURN, BETA and ATLAS can get us there and they read-out over the next 12-18

  11. Slide 11: Disciplined R&D Spend: Responding to Data

    Slide 11: Disciplined R&D Spend: Responding to Data

    Disciplined R&D Spend: Responding to Data A Change in Status for Our Internal DP-IV Program DP-IV inhibitors have two potential liabilities Chronic co-substrate inhibition (Substance P, PYY) DP8/9 selectivity (FDA mandated 3-month primate toxicity study) PSN9301 designed to manage both via short act

  12. Slide 12: DP-IV Class: Still a Major Growth Area

    Slide 12: DP-IV Class: Still a Major Growth Area

    DP-IV Class: Still a Major Growth Area DP-IV Patent Estate & License Portfolio Ownership of patent estate for the use of DP-IV inhibitors for the treatment of diabetes, as monotherapy and in combination is a major secondary revenue stream for OSI Acquired as part of $35MM acquisition from Probiodrug

  13. Slide 13: OSIP Portfolio in 4Q2007

    Slide 13: OSIP Portfolio in 4Q2007

    OSIP Portfolio in 4Q2007 Tarceva Franchise & a Quality Emerging Pipeline PRODUCT Pre-clinical/ IND TRACK PHASE I PHASE II PHASE III Marketed Tarceva: 2nd/3rd Line NSCLC Pancreatic Cancer 1st Line NSCLC Adjuvant NSCLC 1st Line Ovarian Cancer Other Indications Oncology: OSI-906 (IGF-1R) OSI-027 TORC1/

  14. Slide 14: Tarceva: Solid Performance Since Launch

    Slide 14: Tarceva: Solid Performance Since Launch

    Tarceva: Solid Performance Since Launch Robust Global Growth of the Brand Continues Quarterly Tarceva Net Sales First 3 quarters of 2007 Worldwide Tarceva Net Sales Were $636 million OSI Co-promotes with Genentech in US (equal profit share economics) Roche Commercializes ex-US (OSI Royalty) Guidance

  15. Slide 15: Tarceva: Competitively Positioned

    Slide 15: Tarceva: Competitively Positioned

    Tarceva: Competitively Positioned Major Potential "Step-Ups" in Value On the Horizon Major Near Term Phase III Data Read-outs: Longer Term Phase II/III Data Read-outs: Study Indication/Use Data SATURN NSCLC: Tarceva Monotherapy as Maintenance Following Front-line Chemotherapy, 850 pts - Label Enabli

  16. Slide 16: Tarceva: Competitively Positioned

    Slide 16: Tarceva: Competitively Positioned

    Tarceva: Competitively Positioned Competitive Landscape Holds Substantially Less Risk NSCLC studies missing endpoints or halted in last 18 months Velcade Telcyta Iressa (Stage III NSCLC Maintenance) Erbitux in front-line combination with Carbo-Taxol Only Erbitux with less common Navelbine/Cisplatin

  17. Slide 17: OSI Oncology R&D Exiting 2007

    Slide 17: OSI Oncology R&D Exiting 2007

    OSI Oncology R&D Exiting 2007 EMT Platform: Leadership in Emerging Field Molecular Targeted Therapies Guided by EMT Biology PTK/EMT inhibitor program has advanced OSI-906 and OSI-027 Historically 5 MTTs advanced to clinic from PFE collaboration (including Tarceva) EMT interest stimulated by sub-set

  18. Slide 18: OSI Oncology R&D Exiting 2007

    Slide 18: OSI Oncology R&D Exiting 2007

    OSI Oncology R&D Exiting 2007 EMT Platform: Leadership in Emerging Field Molecular Targeted Therapies Guided by EMT Biology PTK/EMT Inhibitor Program Has Advanced OSI-906 and OSI-027 Historically 5 MTT's advanced to clinic from PFE collaboration (including Tarceva) EMT interest stimulated by sub-set

  19. Slide 19: OSI Development Portfolio in 4Q2007

    Slide 19: OSI Development Portfolio in 4Q2007

    OSI Development Portfolio in 4Q2007 Quality Candidates in Oncology & Diabetes/Obesity Molecule Disease Target & Differentiation "Step-Up" in Value Data OSI-906 Oncology Potential "First-in-Class" small molecule IGF-1R inhibitor in Phase I trials with demonstrated pre-clinical synergy with Tarceva &

  20. Slide 20: OSI Development Portfolio in 4Q2007

    Slide 20: OSI Development Portfolio in 4Q2007

    OSI Development Portfolio in 4Q2007 Programs With Differentiation Challenges Molecule Disease Target & Profile Challenges Data PSN9301 Diabetes Prandially dosed, short-acting DP-IV inhibitor w/activity in Phase IIa trials & potential for inter-prandial sparing weight-loss & side-effect benefits via

  21. Slide 21: Partnering/Divestiture of Non-Core Assets

    Slide 21: Partnering/Divestiture of Non-Core Assets

    Partnering/Divestiture of Non-Core Assets A Source of Valuable Supplemental Revenue 2007 Licensing of PSN010 (small molecule GKA) to Lilly Core asset partnered due to financial constraints $25MM up-front, up to $360MM milestones & tiered double-digit royalties Licensing of PDGF-aptamer to Ophthotech

  22. Slide 22: OSIP Exiting 2007 Summary

    Slide 22: OSIP Exiting 2007 Summary

    OSIP Exiting 2007 Summary Strongly profitable Company with anticipated 2007 revenues of >$335MM and earnings of >$1.65 from continued operations Core business may generate ~$2 per share in 2008 Flagship asset in Tarceva with strong global growth and significant market expansion opportunities on the

  23. Slide 23: Executing the Tarceva Program

    Slide 23: Executing the Tarceva Program

    Gabriel Leung President, (OSI) Oncology Executing the Tarceva Program

  24. Slide 24: Tarceva: Solid Performance Since Launch

    Slide 24: Tarceva: Solid Performance Since Launch

    Tarceva: Solid Performance Since Launch Robust Global Growth of the Brand Continues Quarterly Tarceva Net Sales First 3 quarters of 2007 Worldwide Tarceva Net Sales Were $636 million OSI Co-promotes with Genentech in US (equal profit share economics) Roche Commercializes ex-US (OSI Royalty) Guidance

  25. Slide 25: Tarceva Potential Growth Drivers

    Slide 25: Tarceva Potential Growth Drivers

    Tarceva Potential Growth Drivers US Growth Drivers Submission of smoking MTD data for NDA Refined efficacy messaging (e.g. rash) Especially in pancreatic cancer Sales force redeployment SATURN & BETA-Lung data in 2H08 Ex-US Growth Drivers Japan launch Pancreatic launch in EU UK revisited SATURN & BE

  26. Slide 26: Tarceva Potential Growth Drivers

    Slide 26: Tarceva Potential Growth Drivers

    Tarceva Potential Growth Drivers US Growth Drivers Submission of smoking MTD data for NDA Refined efficacy messaging (e.g. rash) Especially in pancreatic cancer Sales force redeployment SATURN & BETA-Lung data in 2H08 Ex-US Growth Drivers Japan launch Pancreatic launch in EU UK revisited SATURN & BE

  27. Slide 27: Tarceva Smoker MTD Data Summary

    Slide 27: Tarceva Smoker MTD Data Summary

    Tarceva Smoker MTD Data Summary MTD in NSCLC patients who continue to smoke (300 mg/d) is higher than the MTD in non-smoking NSCLC patients (150 mg/d) Significantly higher Tarceva exposure at 300 mg/d vs 150 mg/d in current smokers Cmin in current smokers at 300 mg/d is similar to historical data (B

  28. Slide 28: Tarceva and Biomarkers

    Slide 28: Tarceva and Biomarkers

    Tarceva and Biomarkers Survival by Rash Grade: BR.21 and PA.3 Rash Evaluable Population (>28 day survival) Survival Probability Survival (Months) 0 6 12 18 24 30 36 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 0.0 Median: 3.42 Months 95% CI: (2.53, 4.14) Median: 7.18 Months 95% CI: (6.08, 9.40) Median: 1

  29. Slide 29: (OSI) Oncology Sales Infrastructure

    Slide 29: (OSI) Oncology Sales Infrastructure

    (OSI) Oncology Sales Infrastructure An Enhanced Role in Tarceva Promotion In Mid-2007 OSI and Genentech Agreed on a Dedicated Tarceva Sales Force OSI Covers 87% of Tarceva Prescribing Universe and 84% of Zip Codes and Supplies 50% of Total U.S. Reps Sales Specialists include numerous award winners f

  30. Slide 30: SATURN & BETA: The Next Step Up for Tarceva

    Slide 30: SATURN & BETA: The Next Step Up for Tarceva

    SATURN & BETA The Next Step Up for Tarceva If both studies are successful... Overcoming the practice economic hurdle SATURN: maintenance Tarceva not displacing chemo use BETA: the added Avastin is a reimbursed Part B drug Overcoming the "superior efficacy" hurdle SATURN: maintenance Tarceva > waitin

  31. Slide 31: SATURN Maintenance 1st-line NSCLC

    Slide 31: SATURN Maintenance 1st-line NSCLC

    SATURN Maintenance 1st-line NSCLC Eligible pts: 1st line Stage IIIB / IV NSCLC Placebo Tarceva Collect tissue Treatment to PD, unacceptable toxicity or death Primary Endpoint: Progression-free survival (Overall population and EGFR+ patients by IHC) N=850 Stratify for EGFR IHC +/- Smoking Status 1st-

  32. Slide 32: SATURN vs BR.21

    Slide 32: SATURN vs BR.21

    SATURN vs BR.21 Moving Tarceva Upstream 1st-line Chemo PD CR/PR/SD Wait for PD BR.21 1st-line Chemo PD CR/PR/SD SATURN TITAN IHC+

  33. Slide 33: BR.21 Subset Data

    Slide 33: BR.21 Subset Data

    BR.21Subset Data Patients with 1 Prior Regimen and CR/PR/SD HR = 0.62 (95% CI, 0.47 - 0.82) Tarceva median PFS = 3.45 mon (n=184) Placebo median PFS = 1.84 mon (n=85)

  34. Slide 34: BR.21 Subset Data: PFS by EGFR Expression

    Slide 34: BR.21 Subset Data: PFS by EGFR Expression

    BR.21Subset Data PFS According to EGFR Protein Expression EGFR IHC+ EGFR IHC- HR = 0.50 (95% CI, 0.36 - 0.69) Tarceva (n=117) Placebo (n=67) HR = 0.80 (95% CI, 0.55 - 1.16) Tarceva (n=93) Placebo (n=48) Tarceva median PFS = 3.68 mon Placebo median PFS = 1.81 mon Tarceva median PFS = 1.87 mon Placebo

  35. Slide 35: BETA-Lung: AT vs T in 2nd-Line NSCLC

    Slide 35: BETA-Lung: AT vs T in 2nd-Line NSCLC

    Phase III N = 650 Recurrent NSCLC Rx'd brain mets and peripheral squamous eligible 1 prior regimen ECOG PS 0 - 2 Consent for archival Dx tissue required Tarceva + placebo Tarceva + Avastin 1:1 Randomization Stratified by PS, Smoking Hx, Gender, Study sites Primary Endpoint: Overall Survival BETA-Lun

  36. Slide 36: Tarceva/Avastin Combination Regimen

    Slide 36: Tarceva/Avastin Combination Regimen

    Tarceva/Avastin The Leading All Targeted Therapy Combination Regimen Protect 2nd-line NSCLC business Could displace chemotherapy in 1st-line NSCLC Potential in other tumor types Attractive for chronic therapy, but can be further improved with oral anti-VEGF agents A/T A/Chemo Chemo N 39 40 41 PFS 4.

  37. Slide 37: Tarceva Potential Growth Drivers

    Slide 37: Tarceva Potential Growth Drivers

    Tarceva Potential Growth Drivers US Growth Drivers Submission of smoking MTD data for NDA Refined efficacy messaging (e.g. rash) Especially in pancreatic cancer Sales force redeployment SATURN & BETA-Lung data in 2H08 Ex-US Growth Drivers Japan launch Pancreatic launch in EU UK revisited SATURN & BE

  38. Slide 38: Tarceva Other Tumor Types

    Slide 38: Tarceva Other Tumor Types

    Tarceva Other Tumor Types Planning Phase III registration study in hepatocellular carcinoma Nexavar + Tarceva vs Nexavar Phase III 830 patient front-line maintenance study in ovarian cancer (EORTC) Over 200 IST and CTEP collaborative programs across multiple disease settings help to pave the way and

  39. Slide 39: Historical Comparison of Tarceva, A+T, and Nexavar in HCC

    Slide 39: Historical Comparison of Tarceva, A+T, and Nexavar in HCC

    Historical Comparison of Tarceva, A+T, and Nexavar in HCC A/T Phase II Data Suggests Anti-EGFR/VEGF (Angiogenesis) Combination Therapy Can Dramatically Improve Survival

  40. Slide 40: Tarceva Launching New Paradigms

    Slide 40: Tarceva Launching New Paradigms

    Tarceva Launching New Paradigms Chemotherapy paradigm Tarceva can be a better choice than conventional cytotoxic therapy Chronic maintenance paradigm Tarceva po QD enables cancer treatment to be chronic maintenance therapy for remission prolongation, secondary prevention, & possibly primary preventi

  41. Slide 41: Drug Discovery & Translational Research Focused on EMT

    Slide 41: Drug Discovery & Translational Research Focused on EMT

    Drug Discovery & Translational Research Focused on EMT David M. Epstein, Ph.D. Senior Vice President, OSI Oncology

  42. Slide 42: OSI Oncology R&D EMT Platform

    Slide 42: OSI Oncology R&D EMT Platform

    OSI Oncology R&D EMT Platform: Leadership in Emerging Field Our Oncology Thesis: "Delivering an Optimized Drug for a Molecular Target to Selected Patients in the Best Biologically Driven Combination With Other Molecular Targeted Therapies Will be Essential to Delivering the Substantial Efficacy Impr

  43. Slide 43: EMT Research & Development Thesis

    Slide 43: EMT Research & Development Thesis

    Epithelial-to-Mesenchymal Transition Research & Development Thesis Focusing on EMT provides OSI the opportunity to Target unique tumor processes Design rational molecular targeted therapies Develop rational MTT combinations Link targets to molecular markers of progression ? Patient selection markers

  44. Slide 44: EMT Research Thesis Topics

    Slide 44: EMT Research Thesis Topics

    Epithelial-to-Mesenchymal Transition Research & Development Thesis Topics, Issues, How we are thinking about EMT What is EMT and how do we target it? Tumor heterogeneity and multi-targeting Alignment of our current portfolio with the OSI EMT thesis AVEO collaboration

  45. Slide 45: Epithelial-to-Mesenchymal Transition Essential for Normal Development

    Slide 45: Epithelial-to-Mesenchymal Transition Essential for Normal Development

    Epithelial-to-Mesenchymal Transition Essential for Normal Development EMT is an essential cellular program for embryonic development Allows for mobilization of epithelial cells and movement to new sites to form organs and tissue In normal EMT, Epithelial cells de-differentiate to form Mesenchymal ce

  46. Slide 46: Pathological EMT Linked to Solid Tumor Progression

    Slide 46: Pathological EMT Linked to Solid Tumor Progression

    Pathological EMT Linked to Solid Tumor Progression [A] Most solid tumors start in a differentiated, Epithelial phenotype [B] As tumors progress external (stromal / tumor derived factors) and internal signaling events trigger a transition to a Mesenchymal-cell like phenotype [C] Mesenchymal-like tumo

  47. Slide 47: EMT Focus Evolved from Tarceva Response

    Slide 47: EMT Focus Evolved from Tarceva Response

    EMT-focus evolved from need to understand patient response to Tarceva Tarceva is one of the most selective TK inhibitors developed to date EGFR signaling is thought to be an important driver of NSCLC, pancreatic cancer, GBM and other solid tumor types Tarceva Tarceva and EMT From Bench to Bedside an

  48. Slide 48: Tarceva Biomarkers & EMT

    Slide 48: Tarceva Biomarkers & EMT

    Tarceva-sensitive NSCLC cell lines express Epithelial markers (E-Cad) Tarceva-insensitive NSCLC cell lines express Mesenchymal Markers* Data applies to pancreatic cancer and other tumor types ** Data supports concept that proteins important in EMT may be biomarkers for Tarceva E - - cadherin Fibrone

  49. Slide 49: Clinical Correlates of EMT and Sensitivity

    Slide 49: Clinical Correlates of EMT and Sensitivity

    87 patients 74% of patients are E-cadherin positive E-cadherin positive patients have a longer time to progression comparing Tarceva+Chemo with Chemo alone treatment. No difference for response or survival | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

  50. Slide 50: Tarceva Biomarkers: Her3 Mediator of Akt

    Slide 50: Tarceva Biomarkers: Her3 Mediator of Akt

    * Denotes no detected signal PANC1 EGF (10ng/ml) erlotinib (10mM) BxPC3 + + + GAPDH + + + pHER3(Y1289) + + + HER3 + + + pEGFR(Y1068) pAkt(473) + + + pS6(235/236) + + + mesenchymal epithelial EGFR•HER3 AKT S6 proliferation/survival cytoskeletal remodeling erlotinib * * Adapted from Buck et al., Mol.

  51. Slide 51: EMT and Cell Signaling: Basis for New Drug Combinations

    Slide 51: EMT and Cell Signaling: Basis for New Drug Combinations

    EMT and Cell Signaling The Basis for New Drug Combinations EGFR Akt MAPK IGF1R PI3K Ras ZEB1, Snail, Twist Integrins Cox2 Ron/Met PDGFR TGFbR Gene transcription ILK b-Cat Epithelial Ph. Mesenchymal Ph. EMT Gene Transcription Akt MAPK EGFR Del mut Her3 IGF1R PI3K Ras a-Cat b-Cat g-Cat Erlotinib a-Cat

  52. Slide 52: EMT Drug Discovery Strategy

    Slide 52: EMT Drug Discovery Strategy

    EMT Drug Discovery Strategy Focus and Execution Cell Models & Screens Tumor Growth & EMT Targets Drug Discovery To Block EMT, Tumor Growth EMT Tumor Models EMT & Target- Directed Biomarkers Novel Agents & Drug Combinations

  53. Slide 53: Pathological EMT and Tarceva

    Slide 53: Pathological EMT and Tarceva

    Pathological EMT and Tarceva Characterizing Responsiveness In Vitro H1703 Calu6 H441 H292 E-Cadherin Vimentin sensitive refractory Adapted from Thomson et al., Cancer Res., 2005 E-cadherin and vimentin are robust markers to differentiate epithelial and mesenchymal tumor cells

  54. Slide 54: EMT Response Biomarker Correlation

    Slide 54: EMT Response Biomarker Correlation

    EMT Response Biomarker Correlation In Vitro ? In Vivo Models ? Clinical Samples High E-cadherin expression Low E-cadherin expression E-cadherin is expressed but mutated and non-functional Established Tumor Cell Lines Human Tumors Primary Xenografts Conclusion: Resected pancreatic tumors are E-cadher

  55. Slide 55: EMT and Tumor Heterogeneity

    Slide 55: EMT and Tumor Heterogeneity

    EMT and Tumor Heterogeneity The Basis For Seeking New Drug Combinations Tumor center is epithelial; invasive front is mesenchymal Tarceva might be expected to have greater activity on the epithelial portion of the tumor and less on the mesenchymal region Heterogeneity ? Multi-targeting OSI EMT bioma

  56. Slide 56: EMT and Cell Signaling: Current Portfolio

    Slide 56: EMT and Cell Signaling: Current Portfolio

    EMT and Cell Signaling Current Portfolio EGFR Akt MAPK IGF1R PI3K Ras ZEB1, Snail, Twist Integrins Cox2 Ron/Met PDGFR TGFbR Gene transcription ILK b-Cat Epithelial Ph. Mesenchymal Ph. EMT Gene Transcription Akt MAPK EGFR Del mut Her3 IGF1R PI3K Ras a-Cat b-Cat g-Cat Erlotinib a-Cat g-Cat b-Cat E-cad

  57. Slide 57: Exploiting EGFR-TKI Mediated Resistance

    Slide 57: Exploiting EGFR-TKI Mediated Resistance

    Alternate RTKs (IGF1R) EGFR EGFR Raf Erk erlotinib Proliferation / Cell Cycle Progression PI3K Akt mTOR S6 PDK1 OSI-906 EGFR HER3 erlotinib Exploiting EGFR-TKI Mediated Resistance Small Molecule-TKI Blockade of IGF-1R

  58. Slide 58: Preclinical Profile of IGF-1R Inhibitor OSI-906

    Slide 58: Preclinical Profile of IGF-1R Inhibitor OSI-906

    EMT and Cell Signaling Preclinical Profile of IGF-1R Inhibitor (OSI-906) A. 0 4 8 12 16 20 24 0 2 4 6 8 10 0 Time (h) Plasma drug pIGF - - IR Plasma Drug (mM) 0 4 8 12 16 24 2 4 6 8 20 40 60 80 100 120 % pIGF-IR content 0 100 200 300 400 500 600 700 800 900 1 11 21 31 41 51 Day % Tumor Volume Contro

  59. Slide 59: EMT-based Drug Combinations: EGFR and IGF-1R

    Slide 59: EMT-based Drug Combinations: EGFR and IGF-1R

    In NSCLC and pancreatic cancer EGFR and IGF-1R combinations show greatest synergy in cells with a competent EGFR-Akt signaling axis Correlates with an ability to reduce phosphorylation of Akt Such a reduction in Akt is not observed in E-cadherin negative cells EMT-based Drug Combinations EGFR and IG

  60. Slide 60: Small Molecule-TKI Blockade of TORC1/TORC2

    Slide 60: Small Molecule-TKI Blockade of TORC1/TORC2

    Exploiting EMT & Resistance Small Molecule-TKI Blockade of TORC1/TORC2 EGFR EGFR growth factor receptors (IGF1R / c-Met / PDGFR) PI3K Akt Raf mTORC2 S6 Erk erlotinib Proliferation / Survival / Cytoskelatal Remodeling Constitutive activity: Mutations of PI3K loss of PTEN PDK1 mTORC1 OSI-027 Rapamycin

  61. Slide 61: EMT and Cell Signaling: New Discovery Programs

    Slide 61: EMT and Cell Signaling: New Discovery Programs

    EMT and Cell Signaling The Basis For New Discovery Programs EGFR Akt MAPK IGF1R PI3K Ras ZEB1, Snail, Twist Integrins Cox2 Ron/Met PDGFR TGFbR Gene transcription ILK b-Cat Epithelial Ph. Mesenchymal Ph. EMT Gene Transcription Akt MAPK EGFR Del mut Her3 IGF1R PI3K Ras a-Cat b-Cat g-Cat Erlotinib a-Ca

  62. Slide 62: OSI-AVEO Collaboration

    Slide 62: OSI-AVEO Collaboration

    OSI-AVEO Collaboration Discovery and Translational Research Discovery and Translational Research Discovery and Translational Research Discovery and Translational Research Discovery and Translational Research AVEO Tumor Model Platform Target-driven tumor models Discovery programs EMT process linked t

  63. Slide 63: EMT Drug Discovery Strategy

    Slide 63: EMT Drug Discovery Strategy

    EMT Drug Discovery Strategy Focus and Execution OSI EMT Discovery Platform Drivers of tumor growth & EMT e.g., RON/cMET, FAK, SRC EMT model systems for drug discovery OSI IP and Technology Development Academic & AVEO collaborations Pharmacological Disruption of EMT Demonstrated and Feasible Yields s

  64. Slide 64: Summary: Focus on EMT & Drug Discovery

    Slide 64: Summary: Focus on EMT & Drug Discovery

    Summary Focus on EMT & Drug Discovery Epithelial tumor cells use EGFR-mediated growth / survival pathways EMT contributes to de novo and acquired resistance to EGFR-TKIs Redundant pathways limit sustained response to EGFR-TKIs Synergistic MTT development (IGF-1R & TORC1/TORC2)

  65. Slide 65: Summary of OSI EMT Research

    Slide 65: Summary of OSI EMT Research

    Summary of OSI EMT Research Building An EMT-Focused Discovery Engine Pioneered understanding of EMT and response to EGFR-TKIs Developing EMT models to understand EGFR TKI resistance, drug combinations, and new EMT-targeted drugs Identified and validated EMT targets for drug development such as RON/M

  66. Slide 66: Development Programs

    Slide 66: Development Programs

    Development Programs Karsten Witt, M.D. Vice President, Clinical Development, OSI Oncology

  67. Slide 67: OSI-906

    Slide 67: OSI-906

    (os1) pharmaceuticals OSI-906

  68. Slide 68: IGF-1R as an Anti-Cancer Target

    Slide 68: IGF-1R as an Anti-Cancer Target

    IGF-1R as an Anti-Cancer Target Rationale IGF-1R widely expressed among epithelial- derived tumors Receptor for both IGF-1 (liver) and IGF-2 (autocrine/paracrine) Tumor xenograft studies with IGF-1R kinase inhibitors and anti-IGF-1R antibodies indicate: Tumors with autocrine overexpression of IGF-2

  69. Slide 69: IGF-1R Inhibitor OSI-906 Proof of Concept

    Slide 69: IGF-1R Inhibitor OSI-906 Proof of Concept

    IGF-1R Inhibitor OSI-906 Proof of Concept Potent compound identified that has 10-50X selectivity versus IR Excellent anti-tumor activity observed in mouse models of human tumor xenografts driven by IGF/IGFR Good synergy in defined tumors with Tarceva Hyperglycemia observed in animal models but only

  70. Slide 70: OSI-906 Differentiation Strategy

    Slide 70: OSI-906 Differentiation Strategy

    OSI-906 Differentiation Strategy First-in-Class oral IGF-1R TKI Potentially more effective than antibodies given its inhibition of the pAKT survival pathway Convenience and flexibility of oral administration Shorter half-life Improved ability to manage adverse effects Short-term discontinuation for

  71. Slide 71: OSI-906-101 Accelerated Phase I Program

    Slide 71: OSI-906-101 Accelerated Phase I Program

    OSI-906-101Accelerated Phase I Program Continuous Daily Dosing Phase I Dose Escalation initiated June 07 n = 3+3 At 'trigger' eg, gr. 2 tox or PK etc, open BID QD Dosing Escalation with expansion at MTD BID Dose Escalation with expansion at RD Starting Dose 10 mg QD 28-Day Treatment Cycle 28-Day Tre

  72. Slide 72: OSI-906-102 Accelerated Phase I Program

    Slide 72: OSI-906-102 Accelerated Phase I Program

    OSI-906-102 Accelerated Phase I Program Intermittent Daily Dosing At 'trigger' eg, gr. 2 tox or PK etc, open S2 followed by S3 QD Day 1-3 Dosing Escalation with expansion at MTD Starting Dose 10 mg QD 14-Day Treatment Cycle 14-Day Treatment Cycle Designed to integrate with FOLFOX or other chemoTx 40

  73. Slide 73: OSI-906 2008 Deliverables

    Slide 73: OSI-906 2008 Deliverables

    OSI-906 2008 Deliverables Ongoing research In-vivo combination studies with MTT and chemotherapy Optimization of PD biomarker assays Identification of potential patient selection markers Progress Phase I studies toward recommended dose 906-101: 2 schedule cohorts (Daily QD and BID dosing on a 28 day

  74. Slide 74: OSI-906-201 Phase I/II Tarceva Combination

    Slide 74: OSI-906-201 Phase I/II Tarceva Combination

    OSI-906-201 Phase I/II Tarceva Combination Tarceva + OSI-906 N ~ 60 Tarceva + placebo N ~ 60 Phase I Dose Escalation Starting at Tarceva 100 mg/d OSI-906 X mg/d N = ~ 25 R PII D Randomize Ongoing Exploration of Potential for a Patient Selection Strategy AVEO Biomarker Collaboration

  75. Slide 75: Summary of OSI-906 Clinical Development Plan

    Slide 75: Summary of OSI-906 Clinical Development Plan

    Summary of OSI-906 Clinical Development Plan Strategic/Tactical positioning First-in-Class oral IGF-1R inhibitor, strong IP position, "hot" target Differentiation First small molecule to clinic, flexibility to dose with other agents, short half-life vs MAb Potential for biomarker driven patient sele

  76. Slide 76: OSI-027

    Slide 76: OSI-027

    (os1) pharmaceuticals OSI-027

  77. Slide 77: mTOR Kinase Inhibitor Project

    Slide 77: mTOR Kinase Inhibitor Project

    mTOR Kinase Inhibitor Project Improved Approach to a Proven Key Target mTOR is a proven pharmacologic target: mTOR signaling is frequently activated (regulated) by mutations (PI-3K) and inactivation (PTEN) Rapamycin analogs (eg. temsirolimus & everolimus) inhibit the function of the mTOR-Raptor comp

  78. Slide 78: OSI-027 Status Update

    Slide 78: OSI-027 Status Update

    OSI-027 Status Update Enabling toxicology studies to prepare regulatory clinical trial submissions completed GMP API completed and prototype drug product formulations on stability Report writing ongoing Phase I protocol in final draft stage EU CTA/IMPD targeted for end of 2007 US IND to follow in 20

  79. Slide 79: OSI-027-101 Phase I: Cyclic and Continuous Dosing

    Slide 79: OSI-027-101 Phase I: Cyclic and Continuous Dosing

    Phase I Dose Escalation N = ~ 15 OSI-027-101 Phase I: Cyclic and Continuous Dosing Daily Dosing (dilution of 1-3d Q7) N < 20 with expansion at RD S3 At 'trigger' eg, g2 tox or PK etc, open S2 and S3 S2 1d Q7 Dosing Escalation N < 20 with expansion at RD 1-3d Q7 Dosing Escalation N < 20 with expansio

  80. Slide 80: OSI-027 Dose Scheduling Study in IGROV1 Tumor Model

    Slide 80: OSI-027 Dose Scheduling Study in IGROV1 Tumor Model

    OSI-027 Dose Scheduling Study in IGROV1 Tumor Model QD, Q2D, Day 1-14 Q4D, Day 1-14 QD, Q2D, Q3D, Q4D, Q7D, Day 1-14

  81. Slide 81: OSI-027 Differentiation Strategy

    Slide 81: OSI-027 Differentiation Strategy

    OSI-027 Differentiation Strategy Torc1 and Torc2 inhibition vs Torc1 only for rapalogues Orally available small molecule with predictable PK/exposure compared to rapalogues Active in many tumor cell lines and xenografts: rapalogue sensitive and resistant Good opportunity for first and Best-in-Class

  82. Slide 82: OSI-930

    Slide 82: OSI-930

    (os1) pharmaceuticals OSI-930

  83. Slide 83: Dual Kit/KDR Inhibitor Rationale

    Slide 83: Dual Kit/KDR Inhibitor Rationale

    Dual Kit/KDR Inhibitor Rationale Kit involvement in cancer Kit mutation and activation in majority of GIST patients Kit mutations in other tumor types (mast cell leukemia, seminoma, AML) Kit expression in small cell lung cancer (-/+ Kit ligand) KDR involvement in cancer KDR-dependant angiogenesis re

  84. Slide 84: Dual Kit/KDR Inhibitor Rationale

    Slide 84: Dual Kit/KDR Inhibitor Rationale

    Dual Kit/KDR Inhibitor Rationale Kit involvement in cancer Kit mutation and activation in majority of GIST patients Kit mutations in other tumor types (mast cell leukemia, seminoma, AML) Kit expression in small cell lung cancer (-/+ Kit ligand) KDR involvement in cancer KDR-dependant angiogenesis re

  85. Slide 85: Dual Kit/KDR Inhibitor Current Status

    Slide 85: Dual Kit/KDR Inhibitor Current Status

    Dual Kit/KDR Inhibitor Current Status OSI-930 Healthy volunteer Phase I study completed (OSI-930-101) PK linear through 300 mg 63 subjects (single dose) 0-300 mg Phase I studies in cancer patients ongoing Single-agent QD and BID dose escalation ongoing (OSI-930-102) Combination with Tarceva initiate

  86. Slide 86: OSI-930-102 Phase I Trial

    Slide 86: OSI-930-102 Phase I Trial

    OSI-930-102 Phase I trial designed to explore QD and BID schedules 27 patients enrolled to date 12 patients QD schedule (50 - 1600 mg) Minimal toxicity Further escalation limited by number of tablets 15 patients BID (400 - 600 mg) DLT in 3 of 8 patients (1 gr. 4 GGT, 2 gr.3 Rash) at 600 mg PK at 600

  87. Slide 87: OSI-930: Summary Plans for 2008

    Slide 87: OSI-930: Summary Plans for 2008

    Complete Phase I program Explore evidence for Kit driven activity (SCLC, 3rd-line GIST) Assess overall data package Dose escalation study in combination with Tarceva Determine if clear differentiation strategy exists while exploring a broad based program with a global partner OSI-930: Summary Plans

  88. Slide 88: Oncology Q&A

    Slide 88: Oncology Q&A

    (os1) pharmaceuticals Oncology Q&A (leader)ship

  89. Slide 89: Overview of Diabetes/Obesity Programs

    Slide 89: Overview of Diabetes/Obesity Programs

    Overview of Diabetes/Obesity Programs Anker Lundemose, M.D., Ph.D. President, (OSI) Prosidion

  90. Slide 90: Value Drivers of OSIP's Diabetes & Obesity Franchise

    Slide 90: Value Drivers of OSIP's Diabetes & Obesity Franchise

    Value Drivers of OSIP's Diabetes & Obesity Franchise DP-IV Patents Estate, Licenses & Revenues PSN821: Novel oral activator of one of the most exciting targets in type 2 diabetes today, with both potential anti-diabetic and appetite suppressing features - entering Phase I Q3 2008 PSN602: Novel obesi

  91. Slide 91: DP-IV Patent Estate & License Portfolio

    Slide 91: DP-IV Patent Estate & License Portfolio

    DP-IV Patent Estate & License Portfolio Strong Potential for Revenue & Cash Flow Ownership/control of patent estate for the use of DP-IV inhibitors for the treatment of Diabetes, as monotherapy and in combination Acquired as part of $35MM acquisition of DP-IV assets from Probiodrug in 2004 Additiona

  92. Slide 92: DP-IV Patent Estate: Januvia Off To A Head Start

    Slide 92: DP-IV Patent Estate: Januvia Off To A Head Start

    DP-IV Patent Estate & License Portfolio Januvia Off To A Head Start I:\Active\OSP17\Research\[DiabetesMarketResearch_JM_v2.xls]For Slides 2003 04 05 06F 07F 08F 09F 10F Sulfonylureas 0.59 0.46 0.48 0.22 0.18 0.17 0.16 0.15 Biguanides 1.22 0.53 0.71 0.68 0.7 0.71 0.72 0.75 Meglitinides and Amino Acid

  93. Slide 93: Type 2 Diabetes is a Progressive Disease

    Slide 93: Type 2 Diabetes is a Progressive Disease

    Type 2 Diabetes is a Progressive Disease Current Treatment Paradigm Years from diagnosis beta-cell function (%) 100 0 Prediabetes Diet & Exercise Monotherapy Combination Therapy Insulin 60 40 20 80 - -5 - -4 - -1 - -2 - -3 6 5 0 1 2 3 4 Type 2 diabetes } - - Metformin - - PPARg agonists KATP channel

  94. Slide 94: Diabetes & Obesity - Major Unmet Medical Needs

    Slide 94: Diabetes & Obesity - Major Unmet Medical Needs

    Diabetes & Obesity - Major Unmet Medical Needs - Our View Effect on Type 2 diabetes disease progression Improved glucose lowering efficacy & improved side effect (S/E) profile Glucose lowering greater than combination of two current agents, with acceptable side-effect profile ^-cell secretagogue - s

  95. Slide 95: OSIP Therapeutic Targets for Type 2 Diabetes & Obesity

    Slide 95: OSIP Therapeutic Targets for Type 2 Diabetes & Obesity

    OSIP Therapeutic Targets for Type 2 Diabetes & Obesity CNS Peripheral Tissues Gut, Liver & Pancreas SUs Metformin Acarbose(r) Avandia Actos Insulin Xenical(r) Meridia(r) Acomplia(r) Byetta(r) Januvia Beta-cell targets: GKA (PSN010), GPR119 (PSN821) Appetite target: SNRI & 5-HT1A (PSN602) Satiety Gut

  96. Slide 96: Update on PSN821

    Slide 96: Update on PSN821

    Update on PSN821 Jim McCormack, Ph.D, D.Sc. Senior Vice President, (OSI) Prosidion

  97. Slide 97: PSN821 is a Novel GPR119 Agonist

    Slide 97: PSN821 is a Novel GPR119 Agonist

    Gut, Liver & Pancreas PSN821 is a Novel GPR119 Agonist One of the Most Exciting Targets in Type 2 Diabetes Today GPR119 GPR119 Receptor expressed in gut and pancreas PSN821 - Novel oral class of drug with potential anti-diabetic and appetite suppressing features PSN821 releases endogenous GLP-1 and

  98. Slide 98: Proposed Mechanisms for GPR119 Agonists Action

    Slide 98: Proposed Mechanisms for GPR119 Agonists Action

    SLOWED DIABETES PROGRESSION WEIGHT LOSS Pancreas GPR119 GLP1R IMPROVED GLUCOSE HANDLING GPR119 GIPR GLP1R cAMP ^ Glucose-stimulated Insulin Secretion ^ b-CELL PROTECTION GLP1 ^ GIP ^ Satiety ^ Food Intake ^ Gastric Emptying ^ Glucagon secretion ^ GPR119 ? Proposed Mechanisms for GPR119 Agonists Acti

  99. Slide 99: GPR119 Localizes to Pancreatic Islets

    Slide 99: GPR119 Localizes to Pancreatic Islets

    GPR119 Localizes to Pancreatic Islets Subset of cells in the islets of Langerhans with strong GPR119 staining Pancreatic exocrine acinar epithelium (negative) Red = GPR119 (alkaline phosphatase chromogen) Blue = nuclear counterstain (hematoxylin) Islet of Langerhans and acini from normal pancreas ob

  100. Slide 100: GPR119 Localizes to Endocrine Cells within Intestinal Villi

    Slide 100: GPR119 Localizes to Endocrine Cells within Intestinal Villi

    GPR119 strong staining in absorptive epithelium within intraepithelial neuroendocrine cells GPR119 Localizes to Endocrine Cells within the Intestinal Villi Longitudinal section of normal small intestine obtained at surgery from a 69 years-old female Red = GPR119 (alkaline phosphatase chromogen) Blue

  101. Slide 101: Insulinotropic & GLP-1otropic Actions in Cells

    Slide 101: Insulinotropic & GLP-1otropic Actions in Cells

    Insulinotropic & GLP-1otropic Actions in Cells Insulin secretion in HIT-T15 cells - -3 - -2 - -1 0 1.0 1.2 1.4 1.6 1.8 2.0 2.2 Log[PSN821] (mM) Insulin secrxn (fold) EC50 = 153 nM Emax = 2.4 Log[PSN821] (mM) - -3 - -2 - -1 0 1 GLP-1 secrxn (fold) 1.0 1.2 1.4 1.6 1.8 2.0 2.2 GLP-1 secretion in GLUTag

  102. Slide 102: GLP-1 Secretion in SD Rats

    Slide 102: GLP-1 Secretion in SD Rats

    GLP-1 Secretion in SD Rats 0 5 10 15 20 25 30 35 Active GLP-1 (pM) T = 0 min T = 45 min ** 0 10 20 30 ** D[GLP-1]0-45min DP-IV Inhibitor + PSN821

  103. Slide 103: Oral Glucose Tolerance Test in Mice

    Slide 103: Oral Glucose Tolerance Test in Mice

    3 g/kg Glc Oral Glucose Tolerance Test in Mice PSN821 DP-IV Inhibitor - -45 0 45 90 135 180 6 8 10 12 14 16 Time (min) [Glucose] (mM) ** ** ** ** * * 0 100 200 300 400 Vehicle DP-IV i PSN821 *** *** Reactive Glc AUC (mM ? 120 min) Cmpd

  104. Slide 104: Inhibition of Gastric Emptying in SD Rats

    Slide 104: Inhibition of Gastric Emptying in SD Rats

    Inhibition of Gastric Emptying in SD Rats Vehicle (20% HP-b-CD) Atropine 0 10 20 30 40 50 60 70 80 90 * * * % Gastric content @ T = 20 min PSN821 Dose 2 PSN821 Dose 3 PSN821

  105. Slide 105: Diabetes Progression in Prediabetic ZDF Rats

    Slide 105: Diabetes Progression in Prediabetic ZDF Rats

    Diabetes Progression in Prediabetic ZDF Rats N.B. Rat iv T1/2s: PSN821: 1.8 h; Vildagliptin: 8.8 h 5 10 15 20 - -5 0 5 10 15 20 25 30 35 40 45 50 Treatment day Fed blood [Glc] (mM) Vehicle Low dose PSN821 High Dose PSN821 10 mg/kg/d Vildagliptin * * * * * * * * * *

  106. Slide 106: Body Weight Loss in Female DIO Rats

    Slide 106: Body Weight Loss in Female DIO Rats

    Body Weight Loss in Female DIO Rats 370 380 390 400 410 420 430 440 450 - -6 - -5 - -4 - -3 - -2 - -1 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 Day Body weight (g) Vehicle 5 ml/kg po PSN821 low dose po PSN821 high dose po PSN699540 high dose po Vildagliptin 10 m

  107. Slide 107: Fat Pad/Leptin/TG Lowering After 28d Dosing to DIO Mice

    Slide 107: Fat Pad/Leptin/TG Lowering After 28d Dosing to DIO Mice

    Vehicle (20% HP-b-CD) 10 mg/kg/d Rimonabant PSN821 DP-IV inhibitor Retroperitoneal Epididymal Total 0.0 0.5 1.0 1.5 2.0 2.5 ** ** * ** * Tissue weight (g) Fat Pads 0 10 20 30 [Leptin] (ng/mL) Vehicle ** Rimon- abant ** PSN821 DP-IV inhibitor Leptin 0.0 0.2 0.4 0.6 0.8 Vehicle DP-IV inhibitor Rimonab

  108. Slide 108: Proposed Mechanisms for GPR119 Agonists Action

    Slide 108: Proposed Mechanisms for GPR119 Agonists Action

    SLOWED DIABETES PROGRESSION WEIGHT LOSS Pancreas GPR119 GLP1R IMPROVED GLUCOSE HANDLING GPR119 GIPR GLP1R cAMP ^ Glucose-stimulated Insulin Secretion ^ b-CELL PROTECTION GLP1 ^ GIP ^ Satiety ^ Food Intake ^ Gastric Emptying ^ Glucagon secretion ^ GPR119 ? Proposed Mechanisms for GPR119 Agonists Acti

  109. Slide 109: Update on PSN602 & PSN010

    Slide 109: Update on PSN602 & PSN010

    Update on PSN602 & PSN010 Jonathan Rachman, M.D., Ph.D. Senior Vice President, (OSI) Prosidion

  110. Slide 110: PSN602

    Slide 110: PSN602

    (os1) pharmaceuticals PSN602 re(new)

  111. Slide 111: PSN602 - A Novel Obesity Approach

    Slide 111: PSN602 - A Novel Obesity Approach

    PSN602 - A Novel Obesity Approach Dual monoamine reuptake inhibitor & 5-HT1A agonist for the treatment of obesity Noradrenaline and serotonin reuptake inhibition ^ appetite reduction Increased noradrenaline activity associated with increases in BP and heart rate; 5-HT1A agonism included to potential

  112. Slide 112: Sibutramine - Phase IIa Study

    Slide 112: Sibutramine - Phase IIa Study

    Sibutramine - Phase IIa Study Approved doses Greater efficacy but not approved due to CV effects Bray et al, Obesity Research 1999, Vol. 7, No. 2, p 193 Sibutramine is associated with dose-related increases in HR and BP which limits its dosing and hence its efficacy

  113. Slide 113: PSN602 - Efficacy in Female DIO Rats

    Slide 113: PSN602 - Efficacy in Female DIO Rats

    PSN602 - Efficacy in Female DIO* Rats *Chronically obese due to high fat feeding for months: "gold standard" obesity model

  114. Slide 114: PSN602 - No Significant Preclinical CV Effects

    Slide 114: PSN602 - No Significant Preclinical CV Effects

    PSN602 - No Significant Preclinical CV Effects At up to 3xED50 24h in acute feeding - -2 0 2 4 6 8 10 12 6.9 mg/kg 13.8 mg/kg PSN602 po 20.7 mg/kg Sibutramine 15 mg/kg po Mean arterial blood pressure (difference from vehicle) *** BP - -20 - -10 0 10 20 30 40 50 60 70 6.9 mg/kg 13.8 mg/kg 20.7 mg/kg

  115. Slide 115: PSN602 - Targeted Design Provides Unique Positioning

    Slide 115: PSN602 - Targeted Design Provides Unique Positioning

    PSN602- Targeted Design Provides Unique Positioning 5-HT1A agonist PSN602 Edronax(r) (Pfizer) Strattera(r) (Lilly) (Depression, ADHD) e.g. Prozac(r) (Lilly) (Depression) Buspar(r) (BMS) PRX-00023 (EPIX) (Anxiolytics) SRI NRI DRI Tesofensine Sibutramine PSN Chemistry Vilazodone

  116. Slide 116: Tesofensine - A Triple Reuptake Inhibitor

    Slide 116: Tesofensine - A Triple Reuptake Inhibitor

    Tesofensine - A Triple Reuptake Inhibitor 24-week dosing Phase IIb study "AEs were mostly mild to moderate: dry mouth, sleep disturbances, nausea, constipation and diarrhea" "Slight increases in heart rate and blood pressure" TIPO-1 results Placebo Tesofensine 0.25 mg Tesofensine 0.5 mg Tesofensine

  117. Slide 117: PSN602 - Potential

    Slide 117: PSN602 - Potential

    PSN602 - Potential PSN602 delivers superior efficacy relative to sibutramine in DIO rats PSN602 has no dopamine reuptake inhibition element PSN602 is designed to avoid increases in heart rate and blood pressure PSN602 may deliver similar efficacy to that seen with Tesofensine in humans without dopam

  118. Slide 118: PSN602 - A Novel Anti-Obesity Candidate

    Slide 118: PSN602 - A Novel Anti-Obesity Candidate

    PSN602 - A Novel Anti-Obesity Candidate PSN602 has the potential to deliver both greater efficacy and an improved side-effect profile compared with existing drugs approved for the treatment of obesity PSN602 is currently undergoing scale-up and regulatory preclinical studies Phase I start planned fo

  119. Slide 119: PSN010

    Slide 119: PSN010

    (os1) pharmaceuticals PSN010 re(new)

  120. Slide 120: PSN010: A Novel Glucokinase Activator

    Slide 120: PSN010: A Novel Glucokinase Activator

    Gut, Liver & Pancreas PSN010 PSN010: A Novel Glucokinase Activator Dual effects in Pancreas and Liver Increased glucose uptake by the liver Stimulates insulin secretion by the pancreas Positioning: Single agent with dual mechanism of action - potentially superior efficacy Program licensed to Eli Lil

  121. Slide 121: (OSI) Prosidion: Closing Remarks

    Slide 121: (OSI) Prosidion: Closing Remarks

    (OSI) Prosidion: Closing Remarks Anker Lundemose, M.D., Ph.D. President, (OSI) Prosidion

  122. Slide 122: Positioning of OSIP's Pipeline

    Slide 122: Positioning of OSIP's Pipeline

    Effect on Type 2 diabetes disease progression Improved glucose lowering efficacy & Improved side effect (S/E) profile Glucose lowering greater than combination of two current agents, with acceptable side-effect profile ^-cell secretagogue - same or better efficacy as sulfonylurea with better S/E pro

  123. Slide 123: Data & Timelines

    Slide 123: Data & Timelines

    Data & Timelines Compound Status Next event Next Key Data expected Nature of Key Data PSN821 Preclinical Phase I initiation Q3 2008 End Q4 2008 Initial Phase I data: Safety, PK and OGTT* PSN602 Preclinical Phase I initiation Q3 2008 End Q4 2008 Initial Phase I data: Safety, PK and appetite * Clinica

  124. Slide 124: Diabetes and Obesity Q & A

    Slide 124: Diabetes and Obesity Q & A

    (os1) pharmaceuticals Diabetes and Obesity Q & A re(new)

  125. Slide 125: Financial Commentary

    Slide 125: Financial Commentary

    Financial Commentary Michael G. Atieh Chief Financial Officer

  126. Slide 126: A Word About Taxes

    Slide 126: A Word About Taxes

    (os1) pharmaceuticals A Word About Taxes ma) YF y a f a if 7f re(new) oe aN Amy & s

  127. Slide 127: OSI's Historical Net Operating Losses: Unrecognized Asset

    Slide 127: OSI's Historical Net Operating Losses: Unrecognized Asset

    OSI's Historical Net Operating Losses Represent a Significant "Unrecognized" Asset OSI will have US and UK NOLs of approximately $1 billion at 12/31/07 NOLs represent the opportunity to offset future taxable income on a dollar for dollar basis However, there are limits on the annual use of NOLs Our

  128. Slide 128: OSI's Historical Net Operating Losses: Unrecognized Asset

    Slide 128: OSI's Historical Net Operating Losses: Unrecognized Asset

    OSI's Historical Net Operating Losses Represent a Significant "Unrecognized" Asset OSI will have US and UK NOL's of approximately $1 Billion at 12/31/07 NOL's represent the opportunity to offset future taxable income on a dollar for dollar basis However, there are limits on the annual use of NOL's O

  129. Slide 129: GAAP Treatment of NOLs

    Slide 129: GAAP Treatment of NOLs

    GAAP Treatment of NOLs OSI's NOLs represent "unrecognized" Deferred Tax Assets Accounting guidelines require OSI to recognize Deferred Tax Assets, provided that NOL "utilization" is deemed likely in a future period For many companies with historical losses, this criteria is typically met in the thir

  130. Slide 130: GAAP Treatment of NOLs

    Slide 130: GAAP Treatment of NOLs

    GAAP Treatment of NOLs OSI's NOL's represent "unrecognized" Deferred Tax Assets Accounting guidelines require OSI to recognize Deferred Tax Assets, provided that NOL "utilization" is deemed likely in a future period For many companies with historical losses, this criteria is typically met in the thi

  131. Slide 131: Financial Commentary

    Slide 131: Financial Commentary

    (os1) pharmaceuticals Financial Commentary ma) YF a a f a if 7f re(new) oe aN HP bee

  132. Slide 132: 2007: A Year of Financial Transformation

    Slide 132: 2007: A Year of Financial Transformation

    2007: A Year of Financial Transformation Demonstrated the significant earning power of "Core" Business Tarceva as primary engine Strong growth on a global basis DP-IV patent estate as secondary engine Deal flow is slowing but royalties are rising fast Streamlined P&L provided leverage We estimate th

  133. Slide 133: 2007: A Year of Financial Transformation

    Slide 133: 2007: A Year of Financial Transformation

    2007: A Year of Financial Transformation Demonstrated the Significant Earning Power of "Core" Business Tarceva as primary Engine Strong growth on a global basis DPIV Patent Estate as secondary Engine Deal flow is slowing but Royalties are rising fast Streamlined P&L provided leverage We estimate the

  134. Slide 134: 2008: A Year of Scientific Transformation

    Slide 134: 2008: A Year of Scientific Transformation

    2008: A Year of Scientific Transformation But With Continued Focus on Financial Discipline Focus R&D efforts on technology and projects where we are or can be industry leaders Key goal is to establish a follow-on portfolio with Core Assets that we own and control Spend high percentage of "D" dollars

  135. Slide 135: 2008: A Strong Financial Follow-On Year to 2007

    Slide 135: 2008: A Strong Financial Follow-On Year to 2007

    2008: A Strong Financial Follow-On Year to 2007 Our Early Assessment We anticipate that global Tarceva sales should grow by >$200 million over 2007 guidance Minimal incremental costs associated with growth DP-IV related royalties may double 2007 results Januvia/Janumet likely to dominate & class may

  136. Slide 136: R&D Spend in 2008 Anticipated to be Approximately $140 M

    Slide 136: R&D Spend in 2008 Anticipated to be Approximately $140 M

    R&D Spend in 2008 Anticipated to be Approximately $140 M

  137. Slide 137: 2008: A Strong Financial Follow-On Year to 2007

    Slide 137: 2008: A Strong Financial Follow-On Year to 2007

    2008: A Strong Financial Follow-On Year to 2007 Our Early Assessment We anticipate that global Tarceva sales should grow by >$200 million over 2007 guidance Marginal costs associated with growth DP-IV related royalties may double 2007 results Januvia/Janumet likely to dominate & class may reach $1.5

  138. Slide 138: 2008: A Strong Financial Follow-On Year to 2007

    Slide 138: 2008: A Strong Financial Follow-On Year to 2007

    2008: A Strong Financial Follow-On Year to 2007 Our Early Assessment We anticipate that global Tarceva sales should grow by >$200 million over 2007 guidance Marginal costs associated with growth DP-IV related royalties may double 2007 results Januvia/Janumet likely to dominate & class may reach $1.5

  139. Slide 139: Financial Q&A

    Slide 139: Financial Q&A

    (os1) pharmaceuticals Financial Q&A ma) YF y a f a if 7f re(new) oe aN Amy & s

  140. Slide 140: Wrap-up and Final Q&A

    Slide 140: Wrap-up and Final Q&A

    $1) pharmaceuticals Wrap-up and Final Q&A re(new)

Source: SEC EDGAR · 8-K filed Nov 29, 2007

More decks from Osi Pharmaceuticals Inc